Pentwater Capital Management LP said it reduced its economic exposure in Ondine Biomedical Inc. to 3.001803% of the company’s outstanding shares as of Sept. 1, down from 4.053088% previously reported.
The investment firm, controlled by Matthew Halbower and structured through MCH PWCM Holdings Inc., held 16,846,666 shares economically via cash-settled swap agreements. Pentwater noted it holds no direct shares in Ondine Biomedical.
The disclosure was filed with the London Stock Exchange’s Regulatory News Service on Sept. 2, following the cross of the 3% threshold on Sept. 1. The position’s value and purpose were not disclosed in the filing.
